Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study.

ABSTRACT:

Objective

To explore the effectiveness and safety of azvudine and nirmatrelvir-ritonavir in a real-world setting.

Methods

This retrospective cohort study included adult patients with confirmed COVID-19 who received azvudine or nirmatrelvir-ritonavir treatment at Shanghai Changhai Hospital between 1 November 2022, and 30 March 2023. Data were collected from the hospital's electronic medical record system using a standardized data extraction form. Propensity score matching (PSM) was used to control for potential confounding factors. The primary outcome was the incidence of composite disease progression, defined as the occurrence of death, ICU admission, invasive respiratory support, or high-flow oxygen therapy. Multivariable Cox regression analysis was performed to identify th

SUBMITTER: Chen J 

PROVIDER: S-EPMC12006181 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature